These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38660145)

  • 41. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
    Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
    Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.
    Yang H; Xu D; Schmid RA; Peng RW
    Ther Adv Med Oncol; 2020; 12():1758835920971421. PubMed ID: 33240401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
    Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
    Front Oncol; 2020; 10():554570. PubMed ID: 33381446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
    Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy and radiation therapy for malignant pleural mesothelioma.
    Alley EW; Katz SI; Cengel KA; Simone CB
    Transl Lung Cancer Res; 2017 Apr; 6(2):212-219. PubMed ID: 28529903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Efficacy and Safety of Nivolumab: Results of a
    Okada M; Kijima T; Aoe K; Kato T; Fujimoto N; Nakagawa K; Takeda Y; Hida T; Kanai K; Imamura F; Oizumi S; Takahashi T; Takenoyama M; Tanaka H; Hirano J; Namba Y; Ohe Y
    Clin Cancer Res; 2019 Sep; 25(18):5485-5492. PubMed ID: 31164373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma.
    Cheng L; Li N; Xu XL; Mao WM
    Curr Drug Targets; 2020; 21(15):1606-1612. PubMed ID: 32682370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for malignant pleural mesothelioma: current status and future directions.
    Dozier J; Zheng H; Adusumilli PS
    Transl Lung Cancer Res; 2017 Jun; 6(3):315-324. PubMed ID: 28713676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.
    Davis A; Ke H; Kao S; Pavlakis N
    Lung Cancer (Auckl); 2022; 13():1-12. PubMed ID: 35264891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
    Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
    Louw A; Badiei A; Creaney J; Chai MS; Lee YCG
    Curr Opin Pulm Med; 2019 Jul; 25(4):354-361. PubMed ID: 31169558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.